#United States #New York #BrainStorm #Peter Pitts #ALS Trial

BrainStorm Cell Therapeutics Strengthens Leadership with FDA Veteran

In a significant move, BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), renowned for its innovative autologous stem cell therapies designed for treating neurodegenerative disorders, has named Peter J. Pitts to its Board of Directors. This appointment, effective immediately, comes at a critical moment as the company prepares to initiate its Phase 3b ENDURANCE trial for ALS (Amyotrophic Lateral Sclerosis) under the FDA's Special Protocol Assessment (SPA). This milestone could potentially revolutionize the treatment landscape for ALS, a condition characterized by severe motor function decline and currently lacking effective long-term therapies.

Peter J. Pitts is celebrated for his extensive expertise in healthcare policy, regulatory science, and has held prominent positions within the FDA, including Associate Commissioner. His appointment is poised to bolster BrainStorm's strategic direction as it embarks on this pivotal clinical trial, a major step towards evaluating the efficacy of its proprietary therapy, NurOwn®. This therapy utilizes autologous mesenchymal stem cells (MSCs) that are engineered to secrete neurotrophic factors—biological signals crucial for neuroprotection and modulating neuroinflammation.

Pitts expressed his enthusiasm for joining BrainStorm during this transformative phase, noting, "BrainStorm is conducting some of the most important and scientifically rigorous work in neurodegenerative medicine today. The FDA's Special Protocol Assessment for this Phase 3b trial is unprecedented in ALS and demonstrates the agency's acknowledgment of both the disease's severity and the robustness of the trial design."

BrainStorm's CEO, Chaim Lebovits, welcomed Pitts to the board, underscoring the importance of his unparalleled regulatory insight as the company approaches this critical juncture. The adjustments in FDA leadership could foster a more conducive environment for scientific innovation, as highlighted by Pitts, who believes the new management has the potential to bring about more patient-centered regulatory practices. In his words, "Patients with terminal ALS do not have the luxury of bureaucratic drift or ideological grandstanding. They need urgency, rigor, and leadership." This commentary speaks volumes to the urgency faced by ALS patients, emphasizing the pressing need for rapid advancements in treatments.

The ENDURANCE trial, the first of its kind to receive such an SPA designation for an ALS therapeutic candidate, aims to further validate the safety and effectiveness of NurOwn. Earlier phases had already begun to shape the understanding of ALS pathophysiology, providing critical insights into how the therapy could potentially improve quality of life for patients. The trial will be crucial in gathering data that could support broader regulatory approvals, possibly allowing for quicker access to this novel therapy for patients in need.

Beyond ALS, BrainStorm is also undertaking research into other degenerative diseases, having successfully completed a Phase 2 multicenter trial involving its MSC-NTF cells targeting progressive multiple sclerosis. The company is not only looking to expand its therapeutic effects in neurodegenerative diseases but is also innovating its exosome-based platform that delivers proteins and nucleic acids—further diversifying its research portfolio.

Pitts' groundbreaking contributions to healthcare also extend to his role as the President and co-founder of the Center for Medicine in the Public Interest (CMPI). His insights on regulatory issues have appeared in major publications, making him a respected voice in healthcare discourse. His new role at BrainStorm aligns with his ongoing commitment to improving patient outcomes through innovative therapies and effective policy-making.

As BrainStorm embarks on the ENDURANCE trial and leverages Pitts’ expertise, many within the ALS community and beyond are hopeful for a new era of treatment possibilities that could radically change patients' lives. The horizon seems promising with an invigorated focus on patient-centered outcomes and evidence-based advancements in therapeutics. BrainStorm Cell Therapeutics’ initiatives today reflect a potential beacon of hope for countless individuals and families grappling with the challenges of neurodegenerative diseases.

For further information, visit BrainStorm Cell Therapeutics.